Full Press Release Details
Press release Regulated information 25 May 2020 20:00 CEST
IRVINE, CA, and HERSTAL, BELGIUM – 25 May 2020 – MDxHealth SA (Euronext Brussels: MDXH) (the "Company" or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announces today in accordance with Article 15 of the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, that as a result of the capital increase that was announced on 27 April 2020 and completed on 15 May 2020 by means of an equity investment in the Company provided by MVM V LP and MVM GP (No.5) LP, funds managed by MVM Partners LLP (collectively "MVM"), the Company's share capital has increased from EUR 56,260,102.01 to EUR 68,998,734.95 and the number of issued and outstanding shares has increased from 70,528,525 to 90,691,449 ordinary shares, through the issuance of a total of 20,162,924 new ordinary shares.
In addition to the outstanding shares, the total number of outstanding subscription rights at the moment of this press release amounts to 6,328,687 which entitles their holders (if exercised) to subscribe to 6,328,687 new shares with voting rights in total.
| For more information: | |
| MDxHealth | |
| info@mdxhealth.com |
Important information
The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.
Attachments
Click here for pdf...